Episode Details
Back to Episodes
Pharmaceutical Executive Daily: New FDA Draft Guidance Targets Gene Therapy Submission Burden
Published 1 month, 1 week ago
Description
In today's Pharmaceutical Executive Daily, Cam Olig of Prescryptive Health touches on the results of a new market access survey, Eli Lilly and Ascidian Therapeutics announce a global research collaboration worth up to $1.9 billion to develop RNA exon editors for inherited kidney diseases, and the FDA issues new draft guidance to reduce the submission burden for gene therapy developers.